Patents by Inventor Jacques Y. Roberge

Jacques Y. Roberge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic CETP inhibitors
    Patent number: 7790770
    Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: September 7, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, Heather Finlay, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
  • DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE
    Publication number: 20100063141
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.
    Type: Application
    Filed: July 15, 2009
    Publication date: March 11, 2010
    Applicant: Theracos, Inc.
    Inventors: Brian Seed, Binhua LV, Jacques Y. Roberge, Yuanwei Chen, Kun Peng, Jiajia Dong, Baihua Xu, Jiyan Du, Lili Zhang, Xinxing Tang, Ge Xu, Yan Feng, Min Xu
  • Urea antagonists of P2Yreceptor useful in the treatment of thrombotic conditions
    Patent number: 7674828
    Abstract: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: March 9, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hannguang J. Chao, Huji Tuerdi, Timothy F. Herpin, Jacques Y. Roberge, Yalei Liu, Michael R. Lawrence, Robert P. Rehfuss, Charles G. Clark, Jennifer X. Qiao, Timur Gungor, Patrick Y. S. Lam, Tammy C. Wang, Rejean Ruel, Alexandre L'Heureux, Carl Thibeault, Gilles Bouthillier, Dora M. Schnur
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7655689
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: February 2, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • BENZYLBENZENE DERIVATIVES AND METHODS OF USE
    Publication number: 20090118201
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Application
    Filed: August 22, 2008
    Publication date: May 7, 2009
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7517904
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: April 14, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • Amino-benzazoles as P2Yreceptor inhibitors
    Patent number: 7470712
    Abstract: The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Grant
    Filed: January 19, 2005
    Date of Patent: December 30, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Timothy F. Herpin, George C. Morton, Robert P. Rehfuss, R. Michael Lawrence, Michael A. Poss, Jacques Y. Roberge, Timur Gungor
  • AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS
    Publication number: 20080275090
    Abstract: The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Application
    Filed: April 17, 2008
    Publication date: November 6, 2008
    Inventors: Timothy F. Herpin, George C. Morton, Robert P. Rehfuss, R. Michael Lawrence, Michael A. Poss, Jacques Y. Roberge, Timur Gungor
  • Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
    Patent number: 7265145
    Abstract: Compounds are provided which are antagonists of the calcium sensing receptor, and have the general formula wherein m is 0, 1, 2, 3 or 4; each X is independently selected from the group consisting of hydrogen, halo, cyano, nitro, OCF3, hydroxy, amino, carboxyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, haloalkyl, alkoxy, alkoxycarbonylalkyl, hydroxycarbonylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkylalkyl, R1O, R1R2N, R1OCO, R1CO, R1R2NCO, R1R2NCONR2a, R1OCONR2a, R1CONR2a, R1S, R1SO, R1SO2, R1R2NSO2, R1R2NSO2NR2a, and R1SO2NR2a; R1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; R2 and R2a are the same or different and are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; n is 1, 2, or 3; W is O or H,R3; R3 is hydrogen or hydroxyl; Ar is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl g
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: September 4, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John K. Dickson, R. Michael Lawrence, Jacques Y. Roberge, David P. Rotella, Wu Yang
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7141578
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: November 28, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • 2-substituted cyclic amines as calcium sensing receptor modulators
    Patent number: 7105537
    Abstract: The present invention relates to modulators of the calcium sensing receptor having the formula I wherein Ar1, X, n, R1, R2, R3 and Q are as defined herein.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: September 12, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Roy J. Vaz, John K. Dickson, Jr., Jacques Y. Roberge, Wu Yang, Timur Gungor, James R. Corte, David P. Rotella, Yufeng Wang
  • Purine inhibitors of phosphodiesterase (PDE) 7
    Patent number: 6838559
    Abstract: Purine phosphodiesterase 7 (PDE 7) inhibitors of the following formulas wherein R1, Z, Y and J are described herein, and analogs thereof are provided which are useful in treated T-cell mediated diseases. R2 is defined by the following (a) heteroaryl, or heterocyclo, either of which may be optionally substituted with one to three groups T1, T2, T3; (b) aryl substituted with one to three groups T1, T2, T3 provided that at least one of T1, T2, T3 is other than H; or (c) aryl fused to a heteroaryl or heterocyclo ring wherein the combined ring system may be optionally substituted with one to three groups T1, T2, T3.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: January 4, 2005
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Wayne Vaccaro, Jacques Y. Roberge, Katerina Leftheris, William J. Pitts, Joseph Barbosa
  • Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
    Publication number: 20040259860
    Abstract: Compounds are provided which are antagonists of the calcium sensing receptor, and have the general formula 1
    Type: Application
    Filed: May 26, 2004
    Publication date: December 23, 2004
    Inventors: John K. Dickson, R. Michael Lawrence, Jacques Y. Roberge, David P. Rotella, Wu Yang
  • Novel 2-substituted cyclic amines as calcium sensing receptor modulators
    Publication number: 20040229860
    Abstract: The present invention relates to modulators of the calcium sensing receptor having the formula I 1
    Type: Application
    Filed: January 27, 2004
    Publication date: November 18, 2004
    Inventors: Ashvinikumar V. Gavai, Roy J. Vaz, John K. Dickson, Jacques Y. Roberge, Wu Yang, Timur Gungor, James R. Corte, David P. Rotella, Yufeng Wang
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20040077605
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: December 18, 2002
    Publication date: April 22, 2004
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • Purine inhibitors of phosphodiesterase (PDE)
    Publication number: 20030100571
    Abstract: Purine phosphodiesterase 7 (PDE 7) inhibitors of the following formulas 1
    Type: Application
    Filed: June 17, 2002
    Publication date: May 29, 2003
    Inventors: Wayne Vaccaro, Jacques Y. Roberge, Katerina Leftheris, William J. Pitts, Joseph Barbosa
  • Imidazoquinoxaline protein tyrosine kinase inhibitors
    Patent number: 6235740
    Abstract: Novel imidazoquinoxalines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: May 22, 2001
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Joel C. Barrish, Ping Chen, Jagabandhu Das, Edwin J. Iwanowicz, Derek J. Norris, Ramesh Padmanabha, Jacques Y. Roberge, Gary L. Schieven